HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Mullins, C. D. Articles by Stoller, J. K. Search for Related Content PubMed PubMed Citation Articles by Mullins, C. D. Articles by Stoller, J. K.

Major Components of the Direct Medical Costs of ₁-Antitrypsin Deficiency^*

^* From the University of Maryland School of Pharmacy (Dr. Mullins and Ms. Wang), Center on Drugs and Public Policy, Baltimore, MD; and the Department of Pulmonary and Critical Care Medicine (Dr. Stoller), The Cleveland Clinic Foundation, Cleveland, OH.

Correspondence to: C. Daniel Mullins, PhD, University of Maryland, Center on Drugs and Public Policy, Second Floor, 515 W Lombard St, Baltimore, MD 21201; e-mail: dmullins{at}rx.umaryland.edu

Study objectives: To examine the sources of the direct medical costs of ₁-antitrypsin (AAT) deficiency based on survey data from affected individuals.

Background: Prior research has reported the total cost of AAT deficiency but has not examined the specific components of the direct medical costs of affected individuals.

Methods: In order to detail the sources of the direct medical costs, we sent surveys to 688 respondents of a previous survey. We estimated the costs in three ways, which differed in the method of managing missing values. With method 1, the group mean value of cost per unit of utilization, multiplied by the occurrences of utilization, was used to replace the missing value. Two sensitivity analyses (ie, methods 2 and 3) were conducted to test the robustness of our estimate. With method 2, values of zero were entered for all missing values. With method 3, the missing values were replaced by the group mean value. The Wilcoxon test was used to test the cost differences between patients of different phenotypes. All cost data were expressed in 1998 US dollars.

Results and conclusions: Two hundred ninety-two individuals responded to the survey. The annual total health-care costs were high (mean range, $36,471 to $46,114; median range, $12,485 to $37,100 [according to the method for managing missing data]) for AAT deficiency. The total costs for individuals with the PI*ZZ phenotype exceeded those for individuals with a non-PI*ZZ phenotype. The use of IV augmentation therapy accounted for more than half of all direct medical costs for the respondents. Besides the costs for therapy with ₁-proteinase inhibitor (Prolastin; Bayer; West Haven, CT), other major cost sources were prescription drugs other than ₁-proteinase inhibitor, hospitalization, health insurance, and physician visits.

Key Words: ₁-antitrypsin deficiency • cost of illness • economics • phenotype • registries

This article has been cited by other articles:

				J K Stoller and L S Aboussouan {alpha}1-Antitrypsin deficiency {middle dot} 5: Intravenous augmentation therapy: current understanding Thorax, August 1, 2004; 59(8): 708 - 712. [Abstract] [Full Text] [PDF]